Reviewed & approved by Dr. Nova Reyes · Last checked 2026-10-25. ← Back to Evidence Library

title: "Desmopressin: What the evidence says" slug: desmopressin status: Draft (v1), pending review by Dr. Nova Reyes (Batch F #70) last_checked: 2026-10-25 evidence_verdict: "Labeled uses: Strong · "Nootropic" use: No human data" card_verdict: "Strong (diabetes insipidus, nocturia, bleeding disorders) · "Nootropic" sprays: No human data · Banned in sport" related: [oxytocin, semax]

Draft (v1), pending review. Not public. · ← Library · DRAFT · not published · last checked 2026-10-25

Desmopressin: what the evidence says

At a glance

What it is: a synthetic 9-amino-acid analog of vasopressin (antidiuretic hormone), sold as DDAVP (injection, tablets), Stimate nasal spray and generics for central diabetes insipidus, bedwetting, nighttime urination and some bleeding disorders. ^{R1, R2, R3} Gray-market sellers market nasal sprays as a "nootropic."

What the evidence says: it is standard replacement therapy in central diabetes insipidus. ^R1 In 385 men with frequent nighttime urination it reduced nighttime voids modestly (about 0.4 fewer per night vs placebo). ^R4 A 1977 study showed it raises clotting factor VIII enough for surgery in some people with mild hemophilia A or von Willebrand disease. ^R5

Biggest risks: boxed warning (injection): low blood sodium (hyponatremia) that can cause seizures, coma, breathing arrest or death; contraindicated with excessive fluid intake and loop diuretics. ^R1 In the nocturia trial, sodium below 130 mmol/L occurred in 2 men on the lower amount and 9 on the higher. ^R4

Rating


Human Human evidence	Strong for central diabetes insipidus, nocturia and mild hemophilia A / von Willebrand disease (labeled) ^{R1, R4, R5}; No human data for gray-market "nootropic" use in healthy adults
Animal Animal / lab evidence	Not reviewed for this page
Regulatory	FDA-approved: DDAVP NDA 018938 (injection) and 019955 (tablets), Stimate NDA 020355, generics ^R2 · boxed hyponatremia warning (injection) ^R1 · WADA: prohibited at all times (S5 masking agent, named) ^R6
Established human dose	For labeled uses: on the FDA labels ^{R1, R3}. Study details lists what trials used

Evidence verdict: Labeled uses: Strong · "Nootropic" use: No human data Card verdict: Strong (diabetes insipidus, nocturia, bleeding disorders) · "Nootropic" sprays: No human data · Banned in sport Card note: Can cause dangerously low sodium, see page.

This page reports what studies used. It is not dosing advice.

Legend: HUMAN data · ANIMAL / LAB data · UNKNOWN · UNVERIFIED: not yet confirmed against a primary source

About the evidence: the nocturia trial was sponsored by the manufacturer, Ferring Pharmaceuticals ^R4; the 1977 study was academic. ^R5

What is it?

Desmopressin acts on kidney V2 receptors to concentrate urine and raises factor VIII and von Willebrand factor; unlike vasopressin it has little blood-pressure effect. ^{R1, R5} Related pages: Oxytocin, Semax.

Does it work?

Human Nocturia (Weiss 2013): 385 men, 3 months: −0.37 to −0.41 nighttime voids vs placebo; about 40 minutes longer to first void. ^R4
Human Hemophilia A / von Willebrand (Mannucci 1977): factor VIII rose 2–6 fold; dental extraction and major surgery done without plasma in several patients. Uncontrolled, small. ^R5

Is it safe?

Human Boxed warning (injection): hyponatremia; severe cases life-threatening. ^R1
Human Nocturia trial: sodium <130 mmol/L in 2 (lower amount) vs 9 (higher amount); both lower-amount cases were men in their 70s. ^R4

Gray-market "research use only" Desmopressin: extra risks

Not the approved product. Gray-market "nootropic" desmopressin sprays have unknown strength. Unknown The main danger, water intoxication and hyponatremia, depends on fluid intake because desmopressin prevents the kidneys from excreting free water ^R1; no human studies evaluate gray-market desmopressin sprays.

What we don't know

Unknown Whether intranasal desmopressin improves memory or focus in healthy adults (no controlled clinical trials support gray-market "nootropic" claims)
Unknown Quality of gray-market sprays

Is it legal?

US: FDA-approved (DDAVP injection NDA 018938, DDAVP tablets NDA 019955, Stimate nasal spray NDA 020355, plus generics) for the uses on each label. ^{R1, R2, R3} EU, UK and others: UNVERIFIED. WADA: prohibited at all times under S5 (diuretics and masking agents; "desmopressin" named). ^R6

Study details

These are amounts researchers used, not recommendations. ### R4 Human RCT: nocturia in men (Weiss 2013) | Study | People / model | Route | Amount used | Follow-up | Reported | Side effects / limitations | Citation | |---|---|---|---|---|---|---|---| | Weiss 2013 | 385 men with nocturia | Orally disintegrating tablet | 50 or 75 mcg | 3 months | −0.37 / −0.41 voids vs placebo | Hyponatremia more with 75 mcg | [PMID 23454402](https://pubmed.ncbi.nlm.nih.gov/23454402/) | ### R5 Human Case series: hemophilia and vWD (Mannucci 1977) | Study | People / model | Route | Amount used | Follow-up | Reported | Side effects / limitations | Citation | |---|---|---|---|---|---|---|---| | Mannucci 1977 | Patients with mild/moderate hemophilia A and von Willebrand disease | Intravenous | 0.3–0.5 mcg/kg | Peri-operative | Factor VIII up 2–6 fold | Uncontrolled | [PMID 67283](https://pubmed.ncbi.nlm.nih.gov/67283/) |

Full reference list (PubMed, ClinicalTrials.gov, openFDA and DailyMed entries checked Oct 25, 2026)

^R1 DailyMed. DDAVP (desmopressin acetate) injection label, Ferring, effective Sep 28, 2022. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=651f6fee-a2c7-431b-8d5d-58b156c72244
^R2 FDA. Drugs@FDA data (openFDA drugsfda), desmopressin: NDA 018938, NDA 019955 (DDAVP), NDA 020355 (Stimate), NDA 219873 (Desmoda), generic ANDAs; checked Oct 25, 2026. https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:desmopressin
^R3 DailyMed. DDAVP tablets label, Ferring, effective Feb 3, 2021. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6d55baa9-2b62-469c-93ae-3909ab249332
^R4 Weiss JP, et al. Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol. 2013. PMID 23454402
^R5 Mannucci PM, et al. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet. 1977. PMID 67283
^R6 WADA. The 2026 Prohibited List (in force 1 January 2026). https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf

Disclaimer

This page is for education and harm reduction, not medical advice or a recommendation to use Desmopressin. Talk to a clinician you trust before using any drug, and report problems to FDA MedWatch (https://www.fda.gov/safety/medwatch).

Approved for Adam Greene by Dr. Nova Reyes, 2026-10-25.